Grants and Contributions:
Title:
Preclinical investigation of BOLD-100 molecular mechanisms associated with susceptibility to treatment, and novel therapeutic combinations
Agreement Number:
948659
Agreement Value:
$422,667.00
Agreement Date:
May 1, 2020 - Jun 30, 2022
Description:
BOLD-100 is a novel therapeutic that synergies with existing drugs to treat cancer. Project investigates the underlying mechanism behind BOLD-100, leading to new treatment combinations in additional cancer indications.
Organization:
National Research Council Canada
Expected Results:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Location:
Vancouver, British Columbia, CA V6C 1E1
Reference Number:
172-2020-2021-Q1-948659
Agreement Type:
Contribution
Report Type:
Grants and Contributions
Recipient Business Number:
748003712
Recipient Type:
For-profit organization
Additional Information:
This agreement has been amended 1 time(s). The end date of this agreements has been modified by 91 days.
Amendment Date
Mar 9, 2022
Recipient's Legal Name:
Bold Therapeutics Inc.
Federal Riding Name:
Vancouver Centre
Federal Riding Number:
59034
Program:
Industrial Research Assistance Program – Contributions to Firms
Program Purpose:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Coverage:
IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation.
NAICS Code:
325410
Amendments: